NCT02127996

GLP-1 Loading During Elective Percutaneous Coronary Intervention

A Study to Investigate the Protective Effects of Glucagon-like Peptide-1 (GLP-1) in Patients Undergoing Elective Angioplasty and Stenting (GOLD-PCI)

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 193 (actual)
• Sponsor: Papworth Hospital NHS Foundation Trust · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Angina is caused by narrowings or blockages within coronary arteries. Coronary angioplasty and stenting is performed for people with angina to improve the blood supply to the heart by placing metal tubes within the artery using balloon inflation. The procedure risks small but significant damage to the heart muscle downstream of the balloon. Glucagon like peptide 1 (GLP 1) is a naturally occurring hormone secreted by cells in the gut in response to food. It acts by stimulating the release of insulin. In the heart it acts to increase glucose uptake into cardiac muscle. GLP-1 can protect the heart and improve heart muscle performance in people with coronary artery disease in physiological studies. This study which assesses whether GLP-1 protects the heart during coronary angioplasty and stenting. The hypothesis is that GLP-1 given during elective coronary angioplasty and stenting will reduce cardiac troponin rise (a measure of heart muscle damage) compared to placebo.

Conditions

• Angina Pectoris
• Myocardial Infarction
• Reperfusion Injury
• Coronary Heart Disease

Interventions

Type	Name	Description
DRUG	GLP-1	GLP-1 (7-36) amide infused at 1.2 pmol/Kg/min
DRUG	placebo	Normal saline

Timeline

• Start date: 2015-03-01
• Primary completion: 2017-03-31
• Completion: 2021-07-01
• First posted: 2014-05-01
• Last updated: 2018-06-06

Locations

1 site across 1 country: United Kingdom